Esophageal cancer is malignancy of the esophagus. There are various subtypes. Esophageal tumors usually lead to dysphagia (difficulty swallowing), pain and other symptoms, and are diagnosed with biopsy. Small and localized tumors are treated with surgery, and advanced tumors are treated with chemotherapy, radiotherapy or combinations. Prognosis depends on the extent of the disease and other medical problems, but is fairly poor.
CDC2/CDK1
expression in esophageal adenocarcinoma and precursor lesions
serves as a diagnostic and cancer progression marker and
potential novel drug target.
PMID: 15725809
CYFRA21-1
a useful marker in diagnosis and prediction
of prognosis of esophageal cancer.
PMID: 11930636
HER-2/neu
the HER-2/neu oncogene product is a
differentiation marker which is lost in esophageal
adenocarcinoma.
PMID: 7904538
IL12/IL18
Serum IL-12 and IL-18 levels might correlate
with a certain depth of invasion and might be useful tumor
markers in patients with esophageal carcinoma.
PMID: 15036653
Other Esophageal Cancer Markers
MVD using pretreatment biopsy specimens is a
potentially useful prognostic marker for CRT in patients with
T(2-4)M(0) esophageal cancer who are treated with CRT.
PMID: 11801548